Prognostic factors and 5-year overall survival in older adults (≥60 years) with Hodgkin lymphoma in Latin America: A multicenter cohort study

A Amy Alvarenga Tanii (1Instituto de Previsión social, Asunción, Paraguay) A Alana von Glasenapp (10Instituto de Previsión Social, Asunción, Paraguay) S Sofía Rivarola (13Hospital Británico de Buenos Aires, Buenos Aires, Argentina) G German Stemmelin (8Hospital Británico de Buenos Aires, Buenos Aires, Argentina) A Ana Oliver (4CASMU, Montevideo, Uruguay) V Victoria Irigoin (6British Hospital, Montevideo, Uruguay/ CASMU, Montevideo, Uruguay, Montevideo, Uruguay) V Virginia Lema Spinelli (4Servicio medico Integral, Montevideo, Uruguay) M Maria Enciso Arrua (1Instituto de Prevision Social, Hematology, Asuncion, Paraguay) J Julio Fernández-Águila (5Gustavo Aldereguía University Hospital, Cienfuegos, Cuba) R Rosa Rios Jimenez (7Hospital Dr Luis Díaz Soto, Cuba, Habana, Cuba) F Fernando Warley (9Universidad del Hospital Italiano de Buenos Aires, Buenos Aires, Argentina) M Maria Orlova (9Hospital Italiano de Buenos Aires, Buenos Aires, Argentina) J Jule Vasquez (11Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru) M miguel Nicolas lopez Caceres (9Clínica Alemana, Santiago, Chile) A Alfredo Quiroz (14Hospital Central IPS, Asuncion, Paraguay) D Denisse Castro (6Hospital Edgardo Rebagliati, Lima, Peru) M Marialejandra Torres Viera (15Clinica Santa Sofia, Caracas, Venezuela) H Henry Quintero (12Universidad Tecnológica de Pereira, Pereira, Colombia) L Luis Mario Villela Martinez (16Hospital Fernando Ocaranza, Hermosillo, Mexico) J Javier Retamales (14Grupo Oncológico Cooperativo Chileno de Investigación (GOCCHI), Santiago, Chile) B Bryan Valcarcel B Brady Beltran (6Hospital Edgardo Rebagliati, Lima, Peru) J Jorge Castillo (1Dana-Farber Cancer Institute, Bing Center for Waldenstrom's Macroglobulinemia, Boston, United States) L Luis Malpica

Abstract

Abstract Background: Data on outcomes and prognostic factors in older adults with Hodgkin lymphoma (HL) from Latin America remain scarce. We aimed to characterize overall survival (OS) and identify clinical predictors of 5-year OS in this population. Methods: We analyzed a multicenter cohort of 241 HL patients, treated with ABVD regimen, aged ≥60 years from Latin America. Clinical, laboratory, and treatment variables were harmonized and cleaned for analysis. Five-year OS was estimated using Kaplan-Meier methods. Univariate Cox regression models tested associations between OS and covariates including age, Ann Arbor stage, lymphocyte count, hemoglobin, and PET response. Variables significant in univariate analyses and clinically relevant were included in a multivariable Cox proportional hazards model. Results: Median age was 68 years (range 60–88), with 61% males. The 5-year OS was 65.2% (95% CI: 58.0–73.3%). In univariate analysis, increasing age (HR per year 1.06, p=0.0018), advanced Ann Arbor stage, lymphopenia (<600/mm³ or <8%; HR=0.43, p=0.007), and anemia (Hb <10 g/dL; HR=0.40, p=0.001) were significantly associated with worse OS. PET response was not significantly associated with OS. In the multivariable model (n=154, 38 events), older age (HR 1.08 per year, p=0.0007), advanced Ann Arbor stage (notably stages IIA, IIIA, IIIB; p<0.05), and lymphopenia (HR 0.39, p=0.023) remained independent predictors of inferior 5-year OS. Hemoglobin was not independently significant after adjustment. Conclusions: Older age, advanced disease stage, and low lymphocyte count independently predict poorer survival in older Latin American patients with HL. These factors should be incorporated into risk stratification and management decisions to improve outcomes. Further research is needed to optimize therapies tailored for this population. Keywords: Hodgkin lymphoma, elderly, Latin America, survival, prognostic factors

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue Supplement 1
Published November 03, 2025
Pages 7145-7145
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (24)

A

Amy Alvarenga Tanii

1Instituto de Previsión social, Asunción, Paraguay

A

Alana von Glasenapp

10Instituto de Previsión Social, Asunción, Paraguay

S

Sofía Rivarola

13Hospital Británico de Buenos Aires, Buenos Aires, Argentina

G

German Stemmelin

8Hospital Británico de Buenos Aires, Buenos Aires, Argentina

A

Ana Oliver

4CASMU, Montevideo, Uruguay

V

Victoria Irigoin

6British Hospital, Montevideo, Uruguay/ CASMU, Montevideo, Uruguay, Montevideo, Uruguay

V

Virginia Lema Spinelli

4Servicio medico Integral, Montevideo, Uruguay

M

Maria Enciso Arrua

1Instituto de Prevision Social, Hematology, Asuncion, Paraguay

J

Julio Fernández-Águila

5Gustavo Aldereguía University Hospital, Cienfuegos, Cuba

R

Rosa Rios Jimenez

7Hospital Dr Luis Díaz Soto, Cuba, Habana, Cuba

F

Fernando Warley

9Universidad del Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

M

Maria Orlova

9Hospital Italiano de Buenos Aires, Buenos Aires, Argentina

J

Jule Vasquez

11Instituto Nacional de Enfermedades Neoplasicas, Lima, Peru

M

miguel Nicolas lopez Caceres

9Clínica Alemana, Santiago, Chile

A

Alfredo Quiroz

14Hospital Central IPS, Asuncion, Paraguay

D

Denisse Castro

6Hospital Edgardo Rebagliati, Lima, Peru

M

Marialejandra Torres Viera

15Clinica Santa Sofia, Caracas, Venezuela

H

Henry Quintero

12Universidad Tecnológica de Pereira, Pereira, Colombia

L

Luis Mario Villela Martinez

16Hospital Fernando Ocaranza, Hermosillo, Mexico

J

Javier Retamales

14Grupo Oncológico Cooperativo Chileno de Investigación (GOCCHI), Santiago, Chile

B

Bryan Valcarcel

B

Brady Beltran

6Hospital Edgardo Rebagliati, Lima, Peru

J

Jorge Castillo

1Dana-Farber Cancer Institute, Bing Center for Waldenstrom's Macroglobulinemia, Boston, United States

L

Luis Malpica